A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab in Patients With nAMD

NCT04632056 · clinicaltrials.gov ↗

COMPLETED

Status

329

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG: Beovu

Sponsor

Novartis Pharmaceuticals